NRx Pharmaceuticals Statistics
Total Valuation
NRXP has a market cap or net worth of $128.04 million. The enterprise value is $122.26 million.
| Market Cap | 128.04M |
| Enterprise Value | 122.26M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026, before market open.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NRXP has 41.91 million shares outstanding. The number of shares has increased by 102.50% in one year.
| Current Share Class | 41.91M |
| Shares Outstanding | 41.91M |
| Shares Change (YoY) | +102.50% |
| Shares Change (QoQ) | +11.62% |
| Owned by Insiders (%) | 4.25% |
| Owned by Institutions (%) | 12.18% |
| Float | 36.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 55.84 |
| Forward PS | 3.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 53.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.29
| Current Ratio | 0.29 |
| Quick Ratio | 0.27 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -110.23% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 128.98% |
| Weighted Average Cost of Capital (WACC) | 16.65% |
| Revenue Per Employee | $79,069 |
| Profits Per Employee | -$846,207 |
| Employee Count | 29 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.32% in the last 52 weeks. The beta is 2.18, so NRXP's price volatility has been higher than the market average.
| Beta (5Y) | 2.18 |
| 52-Week Price Change | +12.32% |
| 50-Day Moving Average | 3.96 |
| 200-Day Moving Average | 2.78 |
| Relative Strength Index (RSI) | 33.01 |
| Average Volume (20 Days) | 874,251 |
Short Selling Information
The latest short interest is 6.20 million, so 14.79% of the outstanding shares have been sold short.
| Short Interest | 6.20M |
| Short Previous Month | 5.40M |
| Short % of Shares Out | 14.79% |
| Short % of Float | 17.14% |
| Short Ratio (days to cover) | 6.69 |
Income Statement
In the last 12 months, NRXP had revenue of $2.29 million and -$24.54 million in losses. Loss per share was -$0.97.
| Revenue | 2.29M |
| Gross Profit | 1.16M |
| Operating Income | -17.19M |
| Pretax Income | -24.54M |
| Net Income | -24.54M |
| EBITDA | -16.99M |
| EBIT | -17.12M |
| Loss Per Share | -$0.97 |
Balance Sheet
The company has $6.71 million in cash and $934,000 in debt, with a net cash position of $5.78 million or $0.14 per share.
| Cash & Cash Equivalents | 6.71M |
| Total Debt | 934,000 |
| Net Cash | 5.78M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | -13.82M |
| Book Value Per Share | -0.41 |
| Working Capital | -17.82M |
Cash Flow
| Operating Cash Flow | -14.93M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 132,000 |
| Net Borrowing | 5.00M |
| Free Cash Flow | -14.93M |
| FCF Per Share | -$0.36 |
Margins
| Gross Margin | 50.46% |
| Operating Margin | -749.63% |
| Pretax Margin | -1,070.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.50% |
| Shareholder Yield | -102.50% |
| Earnings Yield | -19.17% |
| FCF Yield | -11.66% |
Analyst Forecast
The average price target for NRXP is $42.00, which is 1,274.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $42.00 |
| Price Target Difference | 1,274.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 832.19% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 2, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 2, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
NRXP has an Altman Z-Score of -41.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -41.25 |
| Piotroski F-Score | 2 |